Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

'Off-the-Shelf' Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells.

Cells - 2 Oct 2021

Boyd Nicholas, Cartledge Kellie, Cao Huimin, Evtimov Vera, Pupovac Aleta, Trounson Alan, Boyd Richard

Abstract excerpt

Cellular immunotherapy is revolutionizing cancer treatment. However, autologous transplants are complex, costly, and limited by the number and quality of T cells that can be isolated from and expanded for re-infusion into each patient. This paper demonstrates a stromal support cell-free in vitro method for the differentiation of T cells from umbilical cord blood hematopoietic stem cells (HSCs). For each single...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cattle
Share to CD8-Positive T-Lymphocytes
Share to Cell Differentiation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Cytotoxicity, Immunologic

Share to Fetal Blood

Share to Hematopoietic Stem Cells

Share to Immunotherapy

Source

Open in PubMed Open full text

Identifiers

PMID: 34685611
DOI: 10.3390/cells10102631
PMCID: PMC8534391

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

'Off-the-Shelf' Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells.PMID 34685611Read ↗

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapySemantic proximity Read ↗

Advancing cell-based cancer immunotherapy through stem cell engineeringSemantic proximity Read ↗

Serum-free differentiation platform for the generation of B lymphocytes and natural killer cells from human CD34+ cord blood progenitorsSemantic proximity Read ↗

‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cellsSemantic proximity Read ↗

Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapySemantic proximity Read ↗

Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene EditingSemantic proximity Read ↗

A serum- and feeder-free system to generate CD4 and regulatory T cells from human iPSCsSemantic proximity Read ↗

CD62L-selected umbilical cord blood universal CAR T cellsSemantic proximity Read ↗

Efficient Generation of Functional TCRαβ <sup>+</sup> Cytotoxic T Cells from hiPSCs via Small-Molecule ModulationSemantic proximity Read ↗

A Serum- and Feeder-Free System to Generate CD4 and Regulatory T Cells from Human iPSCsSemantic proximity Read ↗

Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.Semantic proximity Read ↗

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.